Diabetes

Strategic Analysis of Optical Imaging Technologies in U.S. Clinical Diagnostics and Drug Discovery Markets

Publication Date	March 2009
Publisher	Frost & Sullivan
Product Type	Report
Pages	142
ISBN Number	not applicable
Product Code	FRS00026

Price

£3,965.00
approximately: $6,004 | €4,425

pdf immediate delivery

Order above formats by FAX

Technical Developments and Rising Uptake in Certain Application Areas Boosts U.S. Optical Imaging

Technologies

in Clinical Diagnostics and Drug Discovery The use of optical technologies in clinics is currently restricted because of the limited validation and low end-user awareness. However, technological advances and manufacturers' focus on promoting end-user education are likely to result in some optical technologies such as optical coherence tomography (OCT) and fluorescence spectroscopy becoming established in certain applications such as ophthalmology, dentistry, and cancer screening over the next five to ten years. ptics-based technologies have the potential to improve the accuracy of pathological diagnosis and expedite the process of drug discovery,the analyst of this research. dditionally, exponential growth in biomarkers and reagent tools support the development of optical tools for drug discovery applications. Optical technologies are likely to be an ideal method for the future as they address breadth of applications, have low costs, and are non-invasive. Overall, this market is still in its infancy though it has made notable development in the last decade. Certain segments have seen moderate to high growth in recent years such as OCT for ophthalmic and dental applications, and fluorescence imaging. Optical technologies in the clinical imaging market have considerable potential for growth in the next five to ten years, stemming from their vital role in the early diagnosis of diseases. Applications in the field of oncology and cardiovascular diseases are likely to be a part of the growing list of applications benefiting from non-invasive optical methods. Developing applications and ease-of-use are likely to drive growth of optical technologies in the drug discovery markets. At the same time, the prevalence and wide acceptance of alternative technologies is deterring manufacturers from investing heavily in the development of innovative optical methods. Furthermore, the lack of sufficient validated data is slowing adoption among physicians for diverse applications. The widespread use of confocal microscopy as a standard practice is limiting the growth of optical methods in in-vitro optical imaging for drug discovery applications. any alternative technologies such as mechanical devices, digital radiography, and fluorescence-based devices have a strong presence in the dental OCT market, making manufacturers reluctant to invest heavily on the development of new optical methods for dental applications,says the analyst. oreover, most physicians outside academia practice evidence-based medicine. Therefore, limited validated clinical data using optical methods is restricting adoption among tier II end users, including physicians in hospitals and clinics outside the academic arena.Emphases on educating physicians, publishing cost-benefit analysis about new technology, and collaborating with academic institutes to generate more validation data for diverse applications are likely to strengthen the presence of optical methods in the clinical imaging markets.